Review

The natural history of Benign Prostatic Hyperplasia
  • Serdar Toksöz
  • Ayhan Dirim
Bull Urooncol 2011; 10: 5-10
The role of inflammation in the etiopathogenesis of Benign Prostatic Hyperplasia (BPH)
  • Ali Tekin
Bull Urooncol 2011; 10: 15-19
Benign prostatic hyperplasia and heredity
  • Mesut Çetinkaya
  • Çetin Volkan Öztekin
Bull Urooncol 2011; 10: 20-22
Benign Prostatic Hyperplasia: not recomended in diagnosis and treatment (Implented with in the historical process, but right now that is not recommended and not recommended guidelines)
  • Şakir Ongün
  • İlhan Çelebi
Bull Urooncol 2011; 10: 23-26
Re-operation rates and possible causes related to minimally invasive and surgical treatments of Benign Prostatic Hyperplasia
  • Serdar Toksöz
  • Hakan Özkardeş
Bull Urooncol 2011; 10: 34-39
Are radiological imagings useful in diagnosis, treatment and follow-up of Benign Prostatic Hyperplasia?
  • Umut Gönülalan
  • Bülent Öztürk
Bull Urooncol 2011; 10: 55-58
The Prostatic Urethral Lift Method: A New Minimally Invasive Modality as an Alternative in the Treatment of Benign Prostatic Hyperplasia
  • Alpaslan Yüksel
  • Ali Tekin
Bull Urooncol 2016; 15: 119-122 DOI: 10.4274/uob.584
Metabolic Syndrome and Benign Prostate Hyperplasia: An Update
  • İlker Tınay
  • Hacı Murat Akgül
  • Yılören Tanıdır
Bull Urooncol 2014; 13: 206-209 DOI: 10.4274/uob.162
Interventional Treatment of Benign Prostatic Hyperplasia on Elderly People: Prostatic Stent and Prostatic Arterial Embolization
  • Eray Hasırcı
  • Mehmet İlteriş Tekin
Bull Urooncol 2014; 13: 210-214 DOI: 10.4274/uob.166
Laparoscopic Simple Prostatectomy
  • Kadir Ömür Günseren
  • Yakup Kordan
  • Hakan Vuruşkan
Bull Urooncol 2014; 13: 215-222 DOI: 10.4274/uob.174
Phytotherapy in Benign Prostatic Hyperplasia
  • Mehmet Kaynar
  • Serdar Göktaş
Bull Urooncol 2014; 13: 236-240 DOI: 10.4274/uob.197
Surgical Treatment Options for High Risk Patients with Benign Prostatic Hyperplasia
  • Eray Hasırcı
  • Ayhan Dirim
  • Hakan Özkardeş
Bull Urooncol 2015; 14: 290-295 DOI: 10.4274/uob.482
Genetic Basis of Benign Prostatic Hyperplasia Etiology
  • Cüneyt Özden
  • Cevdet Serkan Gökkaya
Bull Urooncol 2015; 14: 299-302 DOI: 10.4274/uob.470
The Role of Enflammation as an Etiopathogenetic Mechanism and Treatment Target in Benign Prostatic Hyperplasia
  • Ali Tekin
  • Alpaslan Yüksel
Bull Urooncol 2015; 14: 303-307 DOI: 10.4274/uob.258
The Effects of Medical Treatments Used for Benign Prostatic Hyperplasia on Ejaculation
  • Ali Kayıkçı
  • Coşkun Kaçağan
  • Ali Tekin
Bull Urooncol 2015; 14: 308-311 DOI: 10.4274/uob.277
Alpha Blocker Treatment and Intra-operative Floppy Iris Syndrome
  • Mehmet Emin Özyalvaçlı
  • Ümit Doğan
  • Adnan Gücük
Bull Urooncol 2015; 14: 312-316 DOI: 10.4274/uob.454

Original Article

Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity
  • İsmail Okan Yıldırım
  • Enes Duman
  • Ali Fırat
  • Hüseyin Çelik
  • Kaya Saraç
Bull Urooncol 2018; 17: 14-17 DOI: 10.4274/uob.937
Is Prostate Cancer Related to Low Vitamin D Level?
  • Aytaç Şahin
  • Tuncay Toprak
  • Musab Ali Kutluhan
  • Ahmet Ürkmez
  • Çağlar Yıldırım
  • Ayhan Verit
Bull Urooncol 2019; 18: 113-116 DOI: 10.4274/uob.galenos.2019.1221

Bph

Metabolic syndrome in the etiology of benign prostatic hyperplasia/ lower urinary tract symptoms
  • Polat Türker
  • Cenk M. Yazıcı
Bull Urooncol 2013; 12: 227-231
The current status of prostate-specific antigen in the management of Benign Prostatic Hyperplasia
  • Ali Tekin
Bull Urooncol 2013; 12: 232-236
Urodynamic studies in Benign Prostate Hyperplasia: whom and when?
  • Umut Gönülalan
  • Murat Koşan
Bull Urooncol 2013; 12: 237-241
The role of phosphodiesterase type-5 inhibitors in Benign Prostatic Hyperplasia, current approaches
  • Eray Kemahlı
  • Adnan Gücük
  • Uğur Üyetürk
Bull Urooncol 2013; 12: 242-246
Prostatic inflammation as a target of etiopathogenesis and treatment
  • Murat Koşan
  • Umut Gönülalan
Bull Urooncol 2013; 12: 247-250
Will lasers replace transurethral resection of the prostate for the treatment of BPH?
  • Ali Erol
  • Serhat Dönmezer
  • Erem Kaan Başok
Bull Urooncol 2013; 12: 255-262
Long-term treatment of Benign Prostatic Hyperplasia with the combination of alpha blockers and 5-alpha reductase inhibitors
  • Cevahir Özer
  • Mehmet İlteriş Tekin
Bull Urooncol 2013; 12: 263-266
Monopolar and bipolar transurethral prostate resection in surgical treatment of benign prostatic hyperplasia
  • Eray Hasırcı
  • Ayhan Dirim
Bull Urooncol 2012; 11: 265-269
Statin's role on protection from the benign prostatic hyperplasia and prostate cancer
  • Eray Hasırcı
  • A. İbrahim Oğuzülgen
Bull Urooncol 2012; 11: 270-274
Robot assisted simple prostatectomy: is it rationale?
  • Levent Mert Günay
  • Mehmet Cemil Uygur
Bull Urooncol 2012; 11: 279-281